CNR1 and Insulin resistance: Thus the enhanced potency of MRI-1891 for inhibiting CB1R β-arrestin2 signaling may provide a clinically meaningful therapeutic window in the treatment of insulin resistance, beyond the fact that this compound is peripherally restricted.